Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.60 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | DGKA | P23743 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369084 | 1.00 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL369798 | 1.00 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL26602804 | 1.00 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL369784 | 1.00 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL371275 | 1.00 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL9958966 | 0.91 | MAPT (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL369749 | 0.91 | MAPT (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL367858 | 0.91 | MAPT (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL368664 | 0.91 | MAPT (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL16612104 | 0.90 | PRKCA (0.68) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180940-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. | 2024-06-06 | — | — | US | claimed |
| WO-2024091615-A1 | METHODS OF ADJUVANT TREATMENT FOR ALLERGY IMMUNOTHERAPY | REVELATION BOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| EP-4346896-A1 | MPLA COMPOSITIONS AND METHODS OF USE | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4346766-A1 | METHODS OF TREATING OR PREVENTING ALLERGIES AND CHRONIC NASAL CONGESTION | Revelation Biosciences, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022251444-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. (US) | 2022-12-01 | — | — | WO | claimed |
| US-20200085743-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-19 | — | — | US | claimed |
| WO-2015036044-A1 | CATIONIC LIPID VEHICLES FOR DELIVERY OF TLR7 AGONISTS FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | TELORMEDIX SA (CH) | 2015-03-19 | — | — | WO | claimed |
| US-20150079155-A1 | Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood | BIONEER A/S (DK) | 2015-03-19 | — | — | US | claimed |
| EP-2825158-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | Bioneer A/S (DK) | 2015-01-21 | — | — | EP | claimed |
| WO-2013135800-A1 | CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD | BIONEER A/S (DK) | 2013-09-19 | — | — | WO | claimed |
| EP-2638896-A1 | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood | Bioneer A/S (DK) | 2013-09-18 | — | — | EP | claimed |
| US-20050118108-A1 | Pulmonary delivery of a liquid medicament aerosol | VENTAIRA PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | claimed |
| EP-4384612-A1 | IMPROVED METHOD FOR SMALL RNA PURIFICATION | Mirnagreen S.r.l. (IT) | 2024-06-19 | — | — | EP | disclosed |
| CN-111867634-B | Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers | 阿尔吉法玛公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240180940-A1 | MPLA COMPOSITIONS AND METHODS OF USE | REVELATION BIOSCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| WO-2024091615-A1 | METHODS OF ADJUVANT TREATMENT FOR ALLERGY IMMUNOTHERAPY | REVELATION BOSCIENCES, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-0533410-A1 | Method of administering dipalmitoyl/phosphatidylcholine dispersions | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0533409-A1 | Method and apparatus for administering respirable pharmaceutical particles | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
| EP-0482097-A1 | SURFACTANT COMPOSITIONS AND METHODS | GENENTECH, INC. (US) | 1992-04-29 | — | — | EP | disclosed |
| WO-1991000871-A1 | SURFACTANT COMPOSITIONS AND METHODS | GENENTECH, INC. (US) | 1991-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200085743-A1 | GLUCOSE SENSITIVE COMPOSITIONS FOR DRUG DELIVERY | SLC2A1, SLC2A8, SLC2A4 | PRKCA 2574/4885PRKCE 3399/4885PRKCQ 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.